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Abstract
Background: HIV-infected patients on long-term highly active antiretroviral therapy often present
peculiar patterns of fat redistribution, referred to as lipodystrophy. In spite of recent investigations,
it is not known whether and to what extent the main features of lipodystrophy – that is lipoatrophy
of peripheral fat at face, limbs and buttocks, as well as fat accumulation at breasts, abdomen and
the dorso-cervical region – can be reversible once clinically manifest.
Case presentation: A 35 year old Caucasian HIV infected female developed severe diffuse
lipodystrophy while on highly active antiretroviral therapy. A remarkable increase of breast size, fat
accumulation at waist, and a fat pad on her lumbar spine were paralleled by progressive and
disfiguring lipoatrophy of face, limbs and buttocks. The patient decided to interrupt her therapy
after 20 months, with a stably suppressed viremia and a CD4 lymphocyte count >500/µL. She could
carry on a safe treatment interruption for longer than 4 years. Most sites of fat accumulation
switched to nearly normal appearance, whereas lipoatrophy was substantially unchanged at all
affected sites.
Conclusion: our observation provides pictorial evidence that lipoatrophy may not be reversible
even under ideal circumstances. Therefore, strategies to prevent lipoatrophy should be considered
when defining therapeutic regimens for HIV infected patients, especially those at high risk.
Background
HIV-infected patients on long-term highly active antiret-
roviral therapy (HAART) often present peculiar patterns of
fat redistribution, involving both visceral and peripheral
adipose tissue, referred to as lipodystrophy [1,2]. This
complex condition was recognized shortly after the intro-
duction of HAART; to date, however, it has been poorly
elucidated in terms of pathogenesis [3,4]. Its main fea-
tures are lipoatrophy of peripheral fat at face, limbs and
buttocks, and/or fat accumulation at breasts, abdomen
and the dorso-cervical region [3-5].
Complex methods for objective measurements of fat
deposits on affected sites involve the use of Dual-energy
X-ray absorptiometry, Magnetic Resonance Tomography
or CT scans. These methods, however, are costly and not
always accessible in routine clinical practice. Moreover,
they still lack adequate standardization, so that the diag-
nosis of lipodystrophy more frequently relies on concord-
ant patient's and physician's evaluation [3-5].
Cross sectional cohort studies indicate that lipodystrophy
affects some 50% of patients continually treated with first-
generation antiretroviral drugs for at least 18–24 months.
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Combined or severe abnormalities, however, develop
only in 5 to 20% of affected patients [3-6], more fre-
quently in older patients, females, patients with more
advanced HIV disease and a longer exposure to antiretro-
viral drugs, especially stavudine and/or indinavir [6-8]. As
to the evolution of body fat abnormalities, evidence has
been gathered that once body changes become clinically
evident, they generally tend to persist, improving only in
a minority of cases [9].
Several strategies have been evaluated in clinical trials,
with the aim of controlling such a stigmatizing side-effect.
Switching to regimens including Nucleoside Reverse Tran-
scriptase Inhibitors other than stavudine and/or a Non-
Nucleoside Reverse Transcriptase Inhibitor instead of a
Protease Inhibitor yielded objectively measured, signifi-
cant increases in subcutaneous fat [10-12]; these, how-
ever, were not recorded as significant improvements by
the affected patients, even after a long follow-up. At the
same time, sites of fat accumulation were generally
unmodified in parallel observations [10-12]. Some drugs
are presently under evaluation for lipodystrophy, includ-
ing metformine and rosiglitazone, with inconclusive
results as yet [3,5]. Finally, it is not clear whether and to
what extent treatment interruptions may be helpful once
lipodystrophy is clinically manifest.
Here we report on the evolution of HAART-induced severe
combined lipodystrophy in one patient who carried out a
very long lasting spell of therapy interruption.
Case presentation
A 35 year old Caucasian female was found to be infected
with HIV1 in 1989, when she tested after heterosexual
exposure. She was put on zidovudine in 1995, when her
CD4 lymphocyte count steadily declined. She took the
drug intermittently until 1997, when she was still asymp-
tomatic, with CD4 lymphocytes <100/µL and a high HIV1
viral load (>500 000 copies/mL). In July 1997, she started
her first line HAART regimen including stavudine 30 mg
twice a day (bid), lamivudine 150 mg bid and indinavir
800 mg 3 times a day. At that time her body weight was
stable, her body shape was lean and preserved, with a
body mass index (BMI) of 18.3. Adherence and response
to treatment were optimal; she reached undetectable
viremia (< 400 copies/mL) and a >200/µL CD4 lym-
phocyte gain by the 12th week of treatment. Since April
1998, the patient complained about remarkable breast
size increase, fat accumulation at waist, and a fat pad
grown over her lumbar spine. The pad was 7 × 10 × 3 cm
in size by July, 1998. At that time indinavir was replaced
with ritonavir/saquinavir 400/400 mg bid due to renal
stones. Rapidly progressive, severe lipoatrophy at limbs,
buttocks and face ensued in the following months,
together with a further increase in size of her fat pads.
HIV1 viremia remained constantly undetectable; meta-
bolic parameters were normal throughout follow-up, with
an isolated abnormal value of triglycerides (306 mg/dL)
in August 1998. Adherence to treatment was full until
April 2000, when the CD4 lymphocyte count was >500/
µL. The patient was offered a simplified regimen, which
she refused, preferring a sharp interruption of HAART. At
that time, she did not allow us to take pictures. After inter-
rupting HAART, HIV1 viremia rebounded to lower than
baseline, remaining <100 000 copies/mL (mode, 25 000
copies/mL) thereafter. CD4 lymphocyte counts declined
very slowly; the patient remained asymptomatic, regularly
attending her follow-up visits. Her metabolic parameters,
including triglycerides, remained within the normal range
at all further checks. She decided to carry on without any
treatment for over 4 years, until July 2004, when the CD4
lymphocyte count had dropped to 84/µL. Pads of fat accu-
mulation at waist had reverted to nearly normal appear-
ance; the lumbar pad was no longer appreciable; breasts
were still enlarged, although to a lesser extent (Fig. 1a). At
variance, lipoatrophy was still well evident; the patient
admitted partial improvement at upper extremities,
whereas she found no improvement at all for buttocks
(Fig. 1b) and legs (Fig. 1c and 1d). Her BMI had dropped
to 17.3. The patient was offered a new HAART regimen
including nevirapine 200 mg bid, tenofovir diproxil 300
mg once a day and lamivudine 150 mg bid; adherence was
full until her last visit, on December 23th, 2004, with a
CD4 lymphocyte count of 250/µL and a viral load of 1250
copies/mL.
Our observation provides pictorial evidence that severe
combined lipodystrophy in our patient was only partially
reversible, even under the ideal condition of a long lasting
and safe interruption of HAART. Recent reports indicate
that the loss of CD4 lymphocytes during treatment inter-
ruptions is frequently rapid in patients with a Nadir CD4
lymphocyte count <200/µL and a high rate of cell gain
under treatment, irrespective of the level of CD4 lym-
phocyte count at the interruption of HAART [13,14]. In
spite of that, our patient could safely carry her interrup-
tion on for over 4 years, remaining asymptomatic
throughout the period, with >200 CD4 T-lymphocytes/µL
until late in 2003. She did eat a light and balanced diet;
she reported taking L-carnitine (5 grams/daily) since June,
2000, until June, 2001, whereas she denied taking any
other drug or supplement possibly interfering with lipid
metabolism thereafter. Under these extremely favourable
circumstances, sites of lumbar and waist fat accumulation
reverted to nearly normal appearance, whereas breasts
showed partial improvement (Fig. 1a). Such a clear-cut
reversal of fat accumulation has not been reported in con-
trolled trials investigating the efficacy of therapy switches
[10-12], probably because of persistent interference withBMC Infectious Diseases 2005, 5:80 http://www.biomedcentral.com/1471-2334/5/80
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lipid metabolism caused by the new antiretroviral drugs
[3-5].
Severe lipoatrophy at buttocks and legs, instead, was
unchanged both on patient's and on our judgment (Fig.
1b, 1c and 1d). Although it is plausible that instrumental
measurements at the affected sites might have detected
partial improvements, our observation suggests that the
loss of peripheral adipose tissue caused by HAART [3-
5,15] may not be fully reversible after treatment interrup-
tion, even in the long run.
Conclusion
Lipodystrophy represents a major drawback of antiretrovi-
ral therapy for HIV infection. Its clinical and psychological
impact may ultimately jeopardize HAART efficacy in
many cases [3,5]. At the time of therapy interruption, our
patient declared she would prefer dying rather than living
with such disfiguring changes of her body shape. Recent
studies systematically addressed the impact of severe lipo-
dystrophy on patients' quality of life, documenting that
body habit changes challenge compliance with therapy, as
well as social relationships, performance of daily activi-
ties, sexuality and self-esteem, especially in young women
[16].
As a growing body of clinical evidence suggests that newer
HAART regimens may be less toxic on the adipose tissue,
causing a clear-cut lower rate of body shape changes in the
long run [17], prevention of lipodystrophy should
become a key issue when tailoring individual regimens,
particularly for patients at high risk of developing fat
abnormalities on the basis of the available data.
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